A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetic profile of single doses of letrazuril in patients with
AIDS-related cryptosporidial diarrhea; to determine the dose proportionality of single
escalating doses of letrazuril; to determine steady-state concentrations of letrazuril; to
evaluate the safety and efficacy of escalating doses of letrazuril, compared with placebo,
for patients with AIDS-related cryptosporidial diarrhea.
Letrazuril, the p-fluor analog of diclazuril, has been shown in an animal model to prevent
infections by organisms closely related to the intracellular parasite Cryptosporidium.
Reliable data are needed to show the effectiveness of letrazuril in treating AIDS-related
cryptosporidial diarrhea.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)